{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T20:47:46Z","timestamp":1778878066138,"version":"3.51.4"},"reference-count":3,"publisher":"SAGE Publications","issue":"3","license":[{"start":{"date-parts":[[2010,2,11]],"date-time":"2010-02-11T00:00:00Z","timestamp":1265846400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Ann Pharmacother"],"published-print":{"date-parts":[[2010,3]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Rufinamide is an oral antiepileptic drug indicated for adjunctive therapy in treating generalized seizures associated with Lennox-Gastaut syndrome. Currently, rufinanide is available as 200-mg and 400-mg tablets. A liquid dosage form does not exist at the present time. Lack of a suspension formulation may present an administration problem for many children and adults who are unable to swallow tablets. The availability of a liquid dosage form will provide an easy and accurate way to measure and administer the medication.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective:<\/jats:title>\n                    <jats:p>To determine the stability of both sugar-containing and sugar-free rufinamide suspensions over a 90-day period.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>A suspension of rufinamide 40 mg\/mL was prepared by grinding twelve 400-mg tablets of rufinamide tablets in a glass mortar. Sixty milliliters of Ora-Plus and 60 mL of either Ora-Sweet or Ora-Sweet SF (sugar free) were mixed and added to the powder to make a final volume of 120 mL. Three identical samples of each formulation were prepared and placed in 60-mL amber plastic bottles and were stored at room temperature. A 1-mL sample was withdrawn from each of the 6 bottles with a micropipette immediately after preparation and at 7, 14, 28, 56, and 90 days. After further dilution to an expected concentration of 0.4 mg\/mL, the samples were assayed using high-performance liquid chromatography. Stability was defined as the retention of at least 90% of the initial concentration.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>At least 90% of the initial rufinamide concentration remained throughout the 90-day study period in both preparations. There were no detectable changes in color, odor, taste, and pH and no visible microbial growth.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>Extemporaneously compounded suspensions of rufinamide 40 mg\/mL in a 1:1 mixture of Ora-Plus and Ora-Sweet or Ora-Sweet SF were stable for at least 90 days when stored in 59-mL amber polypropylene plastic bottles at room temperature.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1345\/aph.1m647","type":"journal-article","created":{"date-parts":[[2010,2,11]],"date-time":"2010-02-11T22:44:56Z","timestamp":1265928296000},"page":"462-465","source":"Crossref","is-referenced-by-count":4,"title":["Stability of Extemporaneously Prepared Rufinamide Oral Suspensions"],"prefix":"10.1177","volume":"44","author":[{"given":"David J","family":"Hutchinson","sequence":"first","affiliation":[{"name":"Wegmans School of Pharmacy, St. John Fisher College, Rochester, NY"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yayin","family":"Liou","sequence":"additional","affiliation":[{"name":"Wegmans School of Pharmacy, St. John Fisher College"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Best","sequence":"additional","affiliation":[{"name":"St. John Fisher College;, College of Arts and Sciences, University at Buffalo; Buffalo, NY"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fang","family":"Zhao","sequence":"additional","affiliation":[{"name":"Wegmans School of Pharmacy, St. John Fisher College"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2010,2,11]]},"reference":[{"key":"bibr1-aph.1M647","first-page":"CD003277","volume":"3","author":"Hancock EC","year":"2003","journal-title":"Cochrane Database Syst Rev"},{"key":"bibr2-aph.1M647","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(08)70292-8"},{"key":"bibr3-aph.1M647","volume-title":"Product information. Banzel (rufinamide)","year":"2008"}],"container-title":["Annals of Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1345\/aph.1M647","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1345\/aph.1M647","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T11:07:29Z","timestamp":1777374449000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1345\/aph.1M647"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,2,11]]},"references-count":3,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2010,3]]}},"alternative-id":["10.1345\/aph.1M647"],"URL":"https:\/\/doi.org\/10.1345\/aph.1m647","relation":{},"ISSN":["1060-0280","1542-6270"],"issn-type":[{"value":"1060-0280","type":"print"},{"value":"1542-6270","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,2,11]]}}}